Roche's Fenebrutinib Confirms Potential as First BTK Inhibitor for Relapsing MS in Phase III FENhance-1 Study

The Landmark Phase III Breakthrough in Relapsing Multiple Sclerosis Treatment

On March 2, 2026, Roche announced groundbreaking results from its Phase III FENhance-1 study, confirming fenebrutinib's potential as the first Bruton's tyrosine kinase (BTK) inhibitor for relapsing multiple sclerosis (RMS). 90 89 This oral therapy demonstrated a statistically significant 51% reduction in annualized relapse rate (ARR) compared to teriflunomide, a standard low-efficacy disease-modifying therapy (DMT), over at least 96 weeks. For patients across Europe, where MS affects over 800,000 individuals predominantly with the relapsing form (about 85% of cases), this marks a pivotal step toward high-efficacy oral options that address both peripheral inflammation and central nervous system (CNS) damage. 88

The trial's success builds on prior positive data from FENhance 2 and FENtrepid, positioning fenebrutinib for regulatory submissions to the European Medicines Agency (EMA) and other authorities. European neurologists and researchers, many affiliated with trial sites, hailed the news as a decade-first advancement in slowing disability progression.

Multiple Sclerosis Landscape in Europe: Prevalence and Challenges

Multiple sclerosis (MS) is a chronic autoimmune disease where the immune system attacks the myelin sheath protecting nerve fibers in the brain and spinal cord, leading to inflammation, demyelination, and neurodegeneration. In Europe, prevalence varies from 50-300 per 100,000, with northern countries like Sweden and Scotland reporting the highest rates. Relapsing-remitting MS (RRMS), the most common subtype, features acute relapses followed by recovery periods, affecting 85% of newly diagnosed patients. Progressive forms, including primary progressive MS (PPMS), emerge in 10-15% and drive irreversible disability.

Current DMTs like interferons, glatiramer acetate, and oral agents such as teriflunomide (Aubagio) reduce relapses by 20-30% but fail to fully halt progression or penetrate the CNS effectively. High-efficacy injectables or infusibles (e.g., ocrelizumab/Ocrevus, natalizumab) offer better control but carry risks like infections or PML. Europe's MS community, supported by organizations like the European Multiple Sclerosis Platform (EMSP), seeks brain-penetrant therapies to bridge this gap.

Unveiling Fenebrutinib: Mechanism of a Next-Generation BTK Inhibitor

Fenebrutinib is a highly selective, non-covalent, reversible inhibitor of Bruton's tyrosine kinase (BTK), an enzyme crucial for B-cell activation and microglial function. Step-by-step: BTK signaling drives pathogenic B cells in the periphery, fueling relapses; in the CNS, it activates microglia, exacerbating chronic inflammation and neurodegeneration. Unlike covalent BTK inhibitors (e.g., ibrutinib), fenebrutinib's reversible binding minimizes off-target effects and allows CNS penetration, targeting both relapsing (B-cell driven) and progressive (microglial) biology.

Administered orally twice daily, it boasts optimized pharmacokinetics for consistent coverage. Preclinical and Phase II data (FENopta trial) showed rapid B-cell depletion and low disease activity, paving the way for Phase III. 90

FENhance-1 Study: Design, Patient Cohort, and Headline Results

The FENhance-1 trial (NCT04586010) enrolled 746 adults with RMS across 160 global sites, including major European centers in Germany, Italy, Poland, Spain, and Switzerland. Patients, aged 18-55 with active disease (≥1 relapse in past year or gadolinium-enhancing lesions), were randomized 1:1 to fenebrutinib (120mg BID) or teriflunomide (14mg QD) for ≥96 weeks, with an optional open-label extension. 88

• Primary endpoint: ARR reduced by 51% (p<0.001).
• Secondary: 70% fewer T1-gadolinium-enhancing lesions; 60% reduction in new/enlarging T2 lesions.
• Disability: Favorable trends in 12/24-week confirmed disability progression (cCDP12/cCDP24) using EDSS, T25FW, 9HPT.

Combined with FENhance 2 (59% ARR reduction), this equates to one relapse every 17 years—transformative for RMS management.

Comparative Efficacy: Fenebrutinib Outperforms Teriflunomide

Teriflunomide, an oral pyrimidine synthesis inhibitor, reduces ARR by ~30% but has limited CNS effects. Fenebrutinib's superior ARR reduction (51-59%), lesion control, and progression trends highlight its high-efficacy profile, akin to anti-CD20 therapies but oral and brain-penetrant. No head-to-head with high-efficacy DMTs yet, but BTK's dual mechanism promises broader benefits. 89

In Europe, where 30% of RMS patients remain on low-efficacy orals due to convenience, fenebrutinib could shift paradigms.

Photo by Markus Winkler on Unsplash

Safety and Tolerability: A Favorable Profile Emerges

Safety mirrored teriflunomide: comparable liver enzyme elevations (ALT/AST), with one asymptomatic Hy's Law case each arm (resolved post-discontinuation). No new safety signals; 8 deaths in fenebrutinib arms (various causes) vs 1 in teriflunomide, under review. Over 2,700 exposed across programs. Advantages: no lymphopenia like fingolimod, lower infection risk than anti-CD20s potentially. 90

European Universities at the Forefront: Trial Sites and MS Research Hubs

Europe's robust involvement underscores academic prowess. Sites included University Hospital Tübingen (Germany), University of Milan (Italy), Jagiellonian University (Poland), and University of Barcelona (Spain). These centers, part of networks like ECTRIMS-MSCOMS, contributed data driving the trial's power.

Leading MS hubs: University of Oxford's Nuffield Department of Clinical Neurosciences pioneers BTK research; Karolinska Institutet (Sweden) explores microglial roles; University Hospital Basel (Ludwig Kappos) tests BTKis. Collaborations with Roche amplify university-led innovations.Explore MS research jobs in Europe.

Pharma-Academia Synergies Fueling MS Advances

Roche partners with European academia via ECTRIMS fellowships and Progressive MS Alliance grants. Universities provide trial expertise, biomarker validation (e.g., neurofilament light chain/NfL), and preclinical BTK models. Post-trial, data will fuel PhD projects on CNS inflammation.ECTRIMS Fellowships train next-gen researchers.

For aspiring neurologists, higher-ed research jobs in MS abound at these institutions.

Patient Impact and Broader Therapeutic Horizons

For Europe's 700,000+ RMS patients, fenebrutinib offers convenience without infusions, potentially delaying progression. Real-world cases: Early adopters in Phase II reported sustained remission. Future: Combo therapies, personalized via genetics.

Careers in MS Research: Opportunities Across European Academia

The surge in BTK data boosts demand for postdocs, lecturers in neurology. Institutions like Heidelberg University seek experts in neuroimmunology. Check higher-ed jobs, university jobs, and career advice for roles in MS trials and BTK studies.

Photo by Artyom Korshunov on Unsplash

Regulatory Pathways, Ongoing Trials, and Future Outlook

Roche plans EMA submission Q2 2026, leveraging three positive Phase IIIs. Ongoing: Long-term extensions, head-to-heads. European universities gear for implementation studies.FENhance-1 on ClinicalTrials.gov

• BTK benefits: Dual peripheral/CNS action.
• Risks: Monitor liver, infections.
• Comparisons: Vs ocrelizumab in PPMS.

Conclusion: A New Era for Relapsing MS Treatment in Europe

Fenebrutinib's FENhance-1 success, powered by European academic sites, heralds the first oral BTK inhibitor for RMS. Dive deeper via Rate My Professor, explore higher-ed jobs, or career advice. Share insights in comments below.